143797-62-0

143797-62-0 structure

Name: SB-200646A
Chemical Name: N-(1-Methyl-1H-5-indolyl)-N'-(3-pyridinyl)urea hydrochloride
CAS Number: 143797-62-0
Molecular Formula: C₁₅H₁₅ClN₄O
Molecular Weight: 302.759
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2018-06-12 06:51:37
Modify Date: 2024-01-09 22:15:48
SB-200646A is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo[1][2].

Name	N-(1-Methyl-1H-5-indolyl)-N'-(3-pyridinyl)urea hydrochloride
Synonyms	1-(1-Methyl-1H-indol-5-yl)-3-(3-pyridinyl)urea hydrochloride (1:1) Urea, N-(1-methyl-1H-indol-5-yl)-N'-3-pyridinyl-, hydrochloride (1:1) 1-(1-Methyl-1H-indol-5-yl)-3-pyridin-3-ylurea hydrochloride (1:1) N-(1-Methyl-1H-5-indolyl)-N'-(3-pyridinyl)urea hydrochloride

Description	SB-200646A is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo[1][2].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
Target	5-HT2B Receptor:7.5 (pKi) 5-HT2C Receptor:6.9 (pKi) 5-HT2A Receptor:5.2 (pKi)
In Vitro	SB200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency[1].
In Vivo	SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons[1]. The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1]. Animal Model: Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment)[1] Dosage: 20 mg/kg Administration: Intravenous injection; daily; for 21 days Result: Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.
References	[1]. Blackburn TP, et al. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: An in vivo extracellular single cell study. Synapse. 2006 Jun 15;59(8):502-12. [2]. Kennett GA, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol. 1994 Mar;111(3):797-802. [3]. Theile JW, et al. Role of 5-hydroxytryptamine2C receptors in Ca2+-dependent ethanol potentiation of GABA release onto ventral tegmental area dopamine neurons. J Pharmacol Exp Ther. 2009 May;329(2):625-33.

Molecular Formula	C₁₅H₁₅ClN₄O
Molecular Weight	302.759
Exact Mass	302.093445
Storage condition	2-8°C

143797-62-0	201038-74-6
274252-40-3	1346603-08-4
1431697-90-3	200940-23-4
24570-77-2	791789-61-2
201038-58-6	219963-52-7
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
849349-65-1	127437-46-1